Advertisement
PROK vs RXRX
Which Stock Would AI Choose? ProKidney Corp (PROK) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- PROK is a late clinical-stage cell therapy company pursuing a single lead program, rilparencel, for advanced chronic kidney disease, with a pivotal readout not expected until the second quarter of 2027.
- RXRX is an AI-driven "TechBio" drug discovery company with a broader, diversified pipeline and recurring collaboration revenue from partners including Sanofi and Roche/Genentech.
- Both companies are pre-commercial and cash-consuming, but RXRX holds a materially larger liquidity cushion, while PROK faces higher single-asset concentration risk.
- Recent sentiment has been driven by catalysts in opposite directions: PROK benefited from FDA alignment on a surrogate endpoint, while RXRX balanced a milestone payment against a dilutive equity raise.
- From a market-positioning standpoint, RXRX offers platform diversification and milestone upside, whereas PROK offers a more focused, binary clinical story.
- For additional context, explore PROK Major News and PROK Today's Price Move, along with RXRX Major News and RXRX Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating clinical-stage biotechnology names often weigh two very different risk-reward profiles: a focused, single-candidate story versus a diversified, platform-driven model. This stock comparison examines PROK, ProKidney Corp, a cell therapy developer targeting chronic kidney disease, against RXRX, Recursion Pharmaceuticals, an artificial intelligence (AI) enabled drug discovery company. Both stocks are pre-revenue or generate only modest collaboration income, making cash runway, clinical catalysts, and partnership momentum the primary drivers of relative performance. This analysis is relevant to traders and investors who track biotech catalysts, assess balance-sheet durability, and compare how market positioning differs between a concentrated therapeutic play and a diversified discovery platform.
PROK Overview and Recent Performance
ProKidney Corp (PROK) is a late clinical-stage cell therapy company focused on chronic kidney disease (CKD). Its lead candidate, rilparencel (REACT), is an autologous cell therapy designed to preserve kidney function in patients with advanced CKD and type 2 diabetes. In recent weeks, sentiment has been shaped by steady execution on its pivotal Phase 3 PROACT 1 study. The company reported completing enrollment for the accelerated approval efficacy analysis and reaffirmed FDA alignment allowing eGFR slope (estimated glomerular filtration rate, a measure of kidney function) to serve as a surrogate endpoint. Topline results are anticipated in the second quarter of 2027. Financially, the company ended its most recent quarter with roughly $181.6 million in cash, cash equivalents, and marketable securities, which management expects to fund operations into mid-2027. Revenue remains negligible, and the stock has traded in a comparatively low range, reflecting the binary nature of a single-asset pipeline ahead of its key data readout.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals (RXRX) describes itself as a clinical-stage "TechBio" company that applies an AI-native operating system to decode biology and design drug candidates. Unlike a single-program biotech, Recursion operates multiple clinical-stage assets, including REC-4881 for familial adenomatous polyposis (FAP, an inherited condition marked by colorectal polyps) and REC-1245 in oncology, alongside discovery collaborations with Sanofi, Roche/Genentech, Bayer, and Merck KGaA. In recent market activity, the stock rallied after partner Sanofi optioned an inflammatory-disease candidate, triggering a $10 million milestone payment; however, the move was tempered by a concurrent $200 million underwritten offering priced at $3.25 per share. Recursion has accumulated more than $500 million in cumulative upfront and milestone payments across its partnerships. It held roughly $561 million in cash as of its latest report, with the new raise extending its projected runway into 2029. Sentiment remains mixed as investors weigh platform validation against ongoing cash burn and share dilution.
Trending AI Robots
For traders who prefer a systematic, rules-based approach over manual stock selection, Tickeron's Trending AI Robots page offers a curated view of automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, yet only a focused selection earns a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance history, statistics, and roster of traded tickers, allowing users to match a strategy to current market conditions rather than relying on a one-size-fits-all approach. Because the list is refreshed around prevailing market dynamics, it can serve as a practical starting point for investors researching how automated systems are currently positioned. Explore the Trending AI Robots section to review available bots and their live performance metrics.
Head-to-Head Comparison
The most meaningful contrast between PROK and RXRX lies in business-model breadth and risk concentration. ProKidney is built around a single lead therapy in a well-defined indication, which concentrates both its upside and its downside on one pivotal trial outcome. Recursion spreads risk across multiple internal programs and externally funded collaborations, generating milestone income that partially offsets its research spend even before any product reaches market.
Growth drivers also differ. ProKidney's near-term catalyst is regulatory and clinical: FDA alignment on a surrogate endpoint and the anticipated 2027 topline readout. Recursion's drivers are more numerous but individually smaller, including partner option exercises, new milestone payments, and early clinical data across several assets. On liquidity, Recursion maintains the larger cash position and a longer stated runway, while ProKidney operates with a more modest buffer tied to a mid-2027 horizon. From a sentiment standpoint, both stocks carry the volatility typical of pre-revenue biotechs, but Recursion's frequent equity raises introduce recurring dilution risk, whereas ProKidney's risk skews toward binary trial outcomes. These trade-offs make the two names complementary case studies in how market positioning differs between a concentrated therapeutic bet and a diversified AI-discovery platform.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst density, balance-sheet durability, and relative positioning, Tickeron's AI would likely tilt toward RXRX at present. Recursion's diversified pipeline, established partnership revenue streams, and extended cash runway provide a broader margin of stability than ProKidney's concentrated single-asset profile. However, this is a probabilistic assessment rather than a definitive call: Recursion's recurring dilution and lumpy collaboration revenue temper its appeal, while ProKidney's FDA alignment and focused pivotal program could generate a sharper, catalyst-driven move around its 2027 data readout. A stability-oriented algorithm would probably favor the diversified platform, while a catalyst-focused strategy might assign greater weight to ProKidney's binary but potentially transformative milestone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PROK is a Hold and RXRX is a Hold.
PROK's Indicator enters downward trend
The Aroon Indicator for PROK entered a downward trend on November 11, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 163 of the 186 cases the stock moved lower. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 75 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for PROK turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 44 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PROK's RSI Indicator exited the oversold zone, 27 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where PROK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 202 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.270) is normal, around the industry mean (3.498). P/E Ratio (-2.073) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RXRX in +8.71% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RXRX advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
RXRX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RXRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for RXRX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (3.498). P/E Ratio (-3.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| PROK | RXRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 85% |
| Advances ODDS (%) | 3 days ago 79% | 3 days ago 84% |
| Declines ODDS (%) | 9 days ago 86% | 9 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 67% | N/A |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PROK’s FA Score shows that 1 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).
- PROK’s FA Score: 1 green, 4 red.
- RXRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PROK’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).
- PROK’s TA Score: 4 bullish, 5 bearish.
- RXRX’s TA Score: 3 bullish, 6 bearish.
Price Growth
PROK (@Biotechnology) experienced а +0.89% price change this week, while RXRX (@Biotechnology) price change was -7.47% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
PROK is expected to report earnings on Mar 25, 2027.
RXRX is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PROK and
Correlation & Price change
A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To PROK | 1D Price Change % | ||
|---|---|---|---|---|
| PROK | 100% | +1.80% | ||
| RXRX - PROK | 50% Loosely correlated | +1.13% | ||
| SANA - PROK | 48% Loosely correlated | -5.76% | ||
| EDIT - PROK | 46% Loosely correlated | -4.99% | ||
| NKTX - PROK | 45% Loosely correlated | +9.63% | ||
| TSHA - PROK | 44% Loosely correlated | +0.12% | ||
More | ||||
RXRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | +1.13% | ||
| CRSP - RXRX | 66% Loosely correlated | +1.33% | ||
| PRME - RXRX | 62% Loosely correlated | +10.26% | ||
| BEAM - RXRX | 60% Loosely correlated | +2.62% | ||
| ABSI - RXRX | 60% Loosely correlated | +1.50% | ||
| DNA - RXRX | 57% Loosely correlated | -14.65% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SEEM | 35.65 | 0.74 | +2.12% |
| SEI Select Emerging Markets Equity ETF (SEEM) | |||
| DFLV | 42.22 | 0.29 | +0.69% |
| Dimensional US Large Cap Value ETF (DFLV) | |||
| BNDD | 98.09 | 0.11 | +0.11% |
| Quadratic Deflation ETF (BNDD) | |||
| GIND | 25.51 | -0.01 | -0.04% |
| Goldman Sachs India Equity ETF (GIND) | |||
| AIBD | 50.61 | -2.47 | -4.65% |
| Direxion Daily AI and Big Data Bear 2X ETF (AIBD) | |||